Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae
Malaria is particularly harmful during pregnancy causing anemia in the mother and low birth weight which, in turn, increases infant mortality. Thus, the World Health Organization (WHO) now recommends that all pregnant women who live in malaria endemic areas of Africa should receive sulfadoxine-pyrimethamine (SP) at monthly intervals during the second and third trimesters of pregnancy. Malaria is especially severe during first pregnancies and the value of intermittent preventative treatment with SP during first pregnancies has been clearly shown. However, it is less certain whether multigravidae, who are at less risk, also benefit from intermittent preventative treatment with SP. To investigate this, a trial has been conducted in Gambian multigravidae who were given intermittent preventative treatment with SP or placebo during the second and third trimesters. The prevalence of anemia six weeks after delivery, low birth weight and poor outcome of pregnancy in women in each group were studied.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Primary Purpose: Prevention
|Official Title:||A Randomised, Placebo Controlled Trial of Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae.|
- Hemoglobin concentration at delivery.
- Hemoglobin concentration six weeks after delivery.
|Study Start Date:||July 2002|
|Estimated Study Completion Date:||September 2004|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00120809
|Medical Research Council Laboratories|
|Banjul, Gambia, PO Box 273|
|Study Chair:||Brian Greenwood, MD||London School of Hygiene and Tropical Medicine|